X
skip to main content
Logo
media conference

Press Releases

  • June 12, 2018

    Dr. Victor Ling is among several prominent Chinese Canadians featured in a newly published 180-page, full-colour book titled Celebration: Chinese Canadian Legacies in British Columbia.

  • June 12, 2018

    Three outstanding cancer research teams will receive nearly $13 million to continue their investigations into rare tumours, an inherited disorder (Li-Fraumeni Syndrome) and the use of magnetic resonance imaging (MRI) and ultrasound to improve treatments for breast cancer.

  • May 17, 2018

    A new study led by Dr. Rebecca Auer, a member of TFRI's Oncolytic Virus project and former recipient of a TFRI New Investigator Award, suggests that a common treatment for erectile dysfunction combined with the flu vaccine may be able to help the immune system mop up cancer cells left behind after surgery.

  • May 15, 2018

    Metastatic castration-resistant prostate cancer (mCRPC) patients are now one step closer to more personalized treatment, thanks to a new test that can distinguish who will respond well to standard therapies and who will become resistant to treatment.

  • May 15, 2018

    Findings from a recent study published in Cell are breaking new ground in the pediatric brain cancer world, suggesting medulloblastoma cells can metastasize in an entirely different way than previously assumed.

  • May 15, 2018

    A cancer research team funded partly by The Terry Fox Research Institute has identified the best method for sequencing gene mutations across several of the most common forms of lymphoid cancer.

  • May 15, 2018

    Targeting hypoxia can, in turn, target cancer-initiating cells (C-ICs) in colorectal cancer a study team in Toronto has found. Additionally, the team has discovered a biomarker for hypoxia to identify tumours that would most benefit from this innovative treatment method.

  • May 14, 2018

    The Terry Fox Research Institute (TFRI) is seeking applications for two of its prestigious grant programs: The Terry Fox New Frontiers Program and the Terry Fox New Investigators Awards.

  • May 10, 2018

    A new study led by a team of TFRI-funded researchers has uncovered the mechanisms through which deadly ovarian cancer cells escape the immune system, setting the stage for a better understanding of how and why patients respond to promising new immunotherapies.

  • May 01, 2018

    More findings from TFRI’s prestigious hypoxia team are continuing to change the cancer research landscape when it comes to understanding the role of the mTOR signalling pathway in the development and aggressiveness of prostate cancer.

  • April 25, 2018

    TFRI's Atlantic node and the Beatrice Hunter Cancer Research Institute will hold a joint workshop on May 25 for researchers and students in Atlantic Canada on the subject of "The Many Ways to Science." All details for the meeting can be found at https://www.fourwav.es/view/672/info/ .

  • April 06, 2018

    “If we could determine up front which patients were higher risk we might be able to adapt our treatment, and hopefully improve outcomes for patients,” says TFRI New Investigator Dr. Robert Kridel, a clinician-scientist at Princess Margaret Cancer Centre who is studying follicular lymphoma with his new $450,000 award .

  • March 07, 2018

    Brain cancer research in Manitoba has received a boost with news that a local scientist has won a prestigious cancer research award from the Terry Fox Research Institute. Dr. Sachin Katyal, a biologist at CancerCare Manitoba and the University of Manitoba, is the first researcher in Manitoba to receive the $450,000 Terry Fox New Investigator award for his “quick-to-clinic” personalized medicine approach to better treat patients with glioblastoma multiforme (GBM).

  • March 06, 2018

    Canadian pancreatic cancer researchers are joining forces under a Terry Fox initiative bringing new hope for patients with this deadly disease.

  • February 15, 2018

    A Vancouver team led by TFRI-funded investigator Dr. David Huntsman has discovered an important therapeutic target for treating small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). This is a rare, but extremely lethal, ovarian cancer in young women with no effective treatment.

Back to Top